BRTX (BioRestorative Therapies) Interest Coverage: No Debt (1) (As of Mar. 2026) — 100% Below Median


BRTX BioRestorative Therapies Inc BRTX
51 GF Score
Price $0.41
GF Value $1.52
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is BioRestorative Therapies Interest Coverage?

BioRestorative Therapies BRTX +8.09% 51 Interest Coverage is No Debt (1) as of Mar. 2026, which is 100% below its 10-year median of 10,000.00. GuruFocus rates BRTX with a GF Score™ of 51/100 and a GF Value™ of $1.52 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 377 Biotechnology companies, BioRestorative Therapies ranks better than 99.2% on this metric.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. BioRestorative Therapies's Operating Income for the three months ended in Mar. 2026 was $-3.39 Mil. BioRestorative Therapies's Interest Expense for the three months ended in Mar. 2026 was $0.00 Mil. BioRestorative Therapies has no debt. The higher the ratio, the stronger the company's financial strength is.

Good Sign:

BioRestorative Therapies Inc has no debt.

(1) Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for BioRestorative Therapies's Interest Coverage or its related term are showing as below:

BRTX' s Interest Coverage Range Over the Past 10 Years
Min: No Debt   Med: No Debt   Max: No Debt
Current: No Debt


BRTX's Interest Coverage is ranked better than
99.2% of 377 companies
in the Biotechnology industry
Industry Median: 106.07 vs BRTX: No Debt

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


BioRestorative Therapies  (NAS:BRTX) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


BioRestorative Therapies Interest Coverage Related Terms


BioRestorative Therapies Interest Coverage Historical Data

* Premium members only.

The historical data trend for BioRestorative Therapies's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

BioRestorative Therapies Interest Coverage Chart

BioRestorative Therapies Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Coverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 N/A No Debt No Debt No Debt

BioRestorative Therapies Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only No Debt No Debt No Debt No Debt No Debt

BRTX vs CVKD, JSPR, APRE: Interest Coverage Comparison

For the Biotechnology subindustry, BioRestorative Therapies's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioRestorative Therapies Interest Coverage vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioRestorative Therapies's Interest Coverage distribution charts can be found below:

* The bar in red indicates where BioRestorative Therapies's Interest Coverage falls into.


BRTX
51GF Score
BioRestorative Therapies Inc BRTX
Interest Coverage is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioRestorative Therapies Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

BioRestorative Therapies's Interest Coverage for the fiscal year that ended in Dec. 2025 is calculated as

Here, for the fiscal year that ended in Dec. 2025, BioRestorative Therapies's Interest Expense was $0.00 Mil. Its Operating Income was $-15.65 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

BioRestorative Therapies had no debt (1).

BioRestorative Therapies's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

Here, for the three months ended in Mar. 2026, BioRestorative Therapies's Interest Expense was $0.00 Mil. Its Operating Income was $-3.39 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

BioRestorative Therapies had no debt (1).

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.

Frequently Asked Questions Learn more about Interest Coverage →
What does a Interest Coverage of No Debt <sup>(1)</sup> mean?
BioRestorative Therapies (BRTX) has a Interest Coverage of No Debt (1) as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on BioRestorative Therapies and its competitors. This is 100% below median its historical median of 10,000.00. Over the past decade, BioRestorative Therapies' Interest Coverage has ranged from 10,000.00 to 10,000.00. According to the industry distribution chart, BioRestorative Therapies ranks #3 out of 377 companies in the Biotechnology industry, placing it in the top 0.8%.
Is BioRestorative Therapies' Interest Coverage too high?
BioRestorative Therapies' current Interest Coverage of No Debt (1) is 100% below median its 10-year median of 10,000.00. Over the past 10 years, this metric has ranged from a low of 10,000.00 to a high of 10,000.00. Based on the distribution chart, BioRestorative Therapies ranks #3 out of 377 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, BioRestorative Therapies has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BioRestorative Therapies' Interest Coverage compare to CVKD and JSPR?
According to the Biotechnology industry distribution chart, BioRestorative Therapies ranks #3 out of 377 companies for Interest Coverage. This places BioRestorative Therapies in the top 1% of its industry — outperforming the majority of peers. The industry median Interest Coverage is 106.07. Historically, BioRestorative Therapies' own Interest Coverage has ranged from 10,000.00 to 10,000.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 106.07, based on 377 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on BioRestorative Therapies and its competitors. For the Biotechnology industry, the median Interest Coverage is 106.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioRestorative Therapies's current Interest Coverage is No Debt (1), which is 100% below median its own 10-year median of 10,000.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioRestorative Therapies stock overvalued right now?
Based on GuruFocus' analysis, BioRestorative Therapies (BRTX) is currently considered Possible Value Trap. The stock's GF Value™ is $1.52, compared to a current price of $0.41 — trading 73.1% below its estimated fair value. The current Interest Coverage is No Debt (1), which is 100% below median its 10-year median of 10,000.00. BioRestorative Therapies' overall GF Score™ is 51/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For BioRestorative Therapies (BRTX), the current Interest Coverage is No Debt (1) as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioRestorative Therapies (BRTX) Overvalued in 2026?

Based on GuruFocus' analysis, BioRestorative Therapies stock appears to be undervalued. The current stock price of $0.41 is trading 73.1% below its estimated GF Value™ of $1.52. GuruFocus considers BioRestorative Therapies to be Possible Value Trap.

Key valuation signals for BRTX:

  • Interest Coverage: No Debt (1) (100% below median its 10-year median of 10,000.00)
  • GF Value™: $1.52 vs. price of $0.41 (73.1% below fair value)
  • GF Score™: 51/100 with 3 warning signs

No single metric tells the full story. See the BRTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BioRestorative Therapies Business Description

Other Exchanges 9OF:Germany
Address 40 Marcus Drive, Suite One, Melville, NY, USA, 11747
BioRestorative Therapies Inc is engaged in developing therapeutic products using cell and tissue protocols, involving adult stem cells. The company is pursuing its Disc/Spine Program with initial investigational therapeutic product being called BRTX-100 in the treatment of chronic cervical discogenic pain. The technology is an stem cell injection procedure that may offer relief from lower back pain, buttock and leg pain, and numbness and tingling in the leg and foot. It is also developing ThermoStem Program, a pre-clinical program which involves the use of brown adipose (fat) in connection with the cell-based treatment of type 2 diabetes and obesity as well as hypertension, other metabolic disorders and cardiac deficiencies.
51GF Score

Get the complete analysis for BRTX

Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.41
Price
$1.52
GF Value